Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

William W. Tseng, Adriana Deganutti, May N. Chen, Romaine E. Saxton, Carson D. Liu, G. Chandler, M. Jaffe, T. Brentnall, Kevin Billingsley

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Recent studies indicate that cyclooxygenase-2 (COX-2) is overexpressed in pancreatic adenocarcinoma and may play a critical role in this rapidly progressing form of cancer. A human pancreatic adenocarcinoma cell line, Mia PaCa-2, was incubated for 18 hours with 5 μmol/L of rofecoxib (Vioxx), a selective COX-2 inhibitor. Total RNA was isolated and gene expression analyzed by DNA microarray chips. In a separate experiment, athymic mice were orthotopically injected with 7.5 × 105 Mia PaCa-2 cells through a minilaparotomy. After 1 month, laparotomy was repeated to measure tumor size, and mice were randomized to receive reformulated rodent chow containing either 12.5 mg/kg/day of rofecoxib or no drug for 21 days. Tumor growth was assessed by comparing volume before and after treatment. In vitro, rofecoxib decreased gene expression of cyclin D1/PRAD1, a key component of cell cycle progression, while increasing expression of several cell cycle arrest genes, including p21/WAF1, p33/ING, GADD34, and GADD45 (P <0.05). In vivo, tumor growth was significantly reduced in treated vs. control mice (P <0.05). No systemic toxicity was observed in mice receiving rofecoxib. These data suggest that rofecoxib slows the growth of human pancreatic cancer through changes in gene expression that favor cell cycle arrest.

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume6
Issue number6
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

cdc Genes
Cyclooxygenase 2 Inhibitors
Cell Cycle Checkpoints
Pancreatic Neoplasms
Growth
Neoplasms
Oligonucleotide Array Sequence Analysis
Gene Expression
Laparotomy
Adenocarcinoma
Cyclin D1
Cyclooxygenase 2
Nude Mice
rofecoxib
Rodentia
Cell Cycle
RNA
Cell Line
Pharmaceutical Preparations

Keywords

  • Cell cycle
  • Cyclooxygenase-2
  • Microarray
  • Pancreas cancer
  • Rofecoxib

ASJC Scopus subject areas

  • Surgery

Cite this

Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. / Tseng, William W.; Deganutti, Adriana; Chen, May N.; Saxton, Romaine E.; Liu, Carson D.; Chandler, G.; Jaffe, M.; Brentnall, T.; Billingsley, Kevin.

In: Journal of Gastrointestinal Surgery, Vol. 6, No. 6, 2002, p. 838-844.

Research output: Contribution to journalArticle

Tseng, William W. ; Deganutti, Adriana ; Chen, May N. ; Saxton, Romaine E. ; Liu, Carson D. ; Chandler, G. ; Jaffe, M. ; Brentnall, T. ; Billingsley, Kevin. / Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. In: Journal of Gastrointestinal Surgery. 2002 ; Vol. 6, No. 6. pp. 838-844.
@article{a91640e2405e4f23acd7bb06d77e29af,
title = "Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer",
abstract = "Recent studies indicate that cyclooxygenase-2 (COX-2) is overexpressed in pancreatic adenocarcinoma and may play a critical role in this rapidly progressing form of cancer. A human pancreatic adenocarcinoma cell line, Mia PaCa-2, was incubated for 18 hours with 5 μmol/L of rofecoxib (Vioxx), a selective COX-2 inhibitor. Total RNA was isolated and gene expression analyzed by DNA microarray chips. In a separate experiment, athymic mice were orthotopically injected with 7.5 × 105 Mia PaCa-2 cells through a minilaparotomy. After 1 month, laparotomy was repeated to measure tumor size, and mice were randomized to receive reformulated rodent chow containing either 12.5 mg/kg/day of rofecoxib or no drug for 21 days. Tumor growth was assessed by comparing volume before and after treatment. In vitro, rofecoxib decreased gene expression of cyclin D1/PRAD1, a key component of cell cycle progression, while increasing expression of several cell cycle arrest genes, including p21/WAF1, p33/ING, GADD34, and GADD45 (P <0.05). In vivo, tumor growth was significantly reduced in treated vs. control mice (P <0.05). No systemic toxicity was observed in mice receiving rofecoxib. These data suggest that rofecoxib slows the growth of human pancreatic cancer through changes in gene expression that favor cell cycle arrest.",
keywords = "Cell cycle, Cyclooxygenase-2, Microarray, Pancreas cancer, Rofecoxib",
author = "Tseng, {William W.} and Adriana Deganutti and Chen, {May N.} and Saxton, {Romaine E.} and Liu, {Carson D.} and G. Chandler and M. Jaffe and T. Brentnall and Kevin Billingsley",
year = "2002",
doi = "10.1016/S1091-255X(02)00061-6",
language = "English (US)",
volume = "6",
pages = "838--844",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

AU - Tseng, William W.

AU - Deganutti, Adriana

AU - Chen, May N.

AU - Saxton, Romaine E.

AU - Liu, Carson D.

AU - Chandler, G.

AU - Jaffe, M.

AU - Brentnall, T.

AU - Billingsley, Kevin

PY - 2002

Y1 - 2002

N2 - Recent studies indicate that cyclooxygenase-2 (COX-2) is overexpressed in pancreatic adenocarcinoma and may play a critical role in this rapidly progressing form of cancer. A human pancreatic adenocarcinoma cell line, Mia PaCa-2, was incubated for 18 hours with 5 μmol/L of rofecoxib (Vioxx), a selective COX-2 inhibitor. Total RNA was isolated and gene expression analyzed by DNA microarray chips. In a separate experiment, athymic mice were orthotopically injected with 7.5 × 105 Mia PaCa-2 cells through a minilaparotomy. After 1 month, laparotomy was repeated to measure tumor size, and mice were randomized to receive reformulated rodent chow containing either 12.5 mg/kg/day of rofecoxib or no drug for 21 days. Tumor growth was assessed by comparing volume before and after treatment. In vitro, rofecoxib decreased gene expression of cyclin D1/PRAD1, a key component of cell cycle progression, while increasing expression of several cell cycle arrest genes, including p21/WAF1, p33/ING, GADD34, and GADD45 (P <0.05). In vivo, tumor growth was significantly reduced in treated vs. control mice (P <0.05). No systemic toxicity was observed in mice receiving rofecoxib. These data suggest that rofecoxib slows the growth of human pancreatic cancer through changes in gene expression that favor cell cycle arrest.

AB - Recent studies indicate that cyclooxygenase-2 (COX-2) is overexpressed in pancreatic adenocarcinoma and may play a critical role in this rapidly progressing form of cancer. A human pancreatic adenocarcinoma cell line, Mia PaCa-2, was incubated for 18 hours with 5 μmol/L of rofecoxib (Vioxx), a selective COX-2 inhibitor. Total RNA was isolated and gene expression analyzed by DNA microarray chips. In a separate experiment, athymic mice were orthotopically injected with 7.5 × 105 Mia PaCa-2 cells through a minilaparotomy. After 1 month, laparotomy was repeated to measure tumor size, and mice were randomized to receive reformulated rodent chow containing either 12.5 mg/kg/day of rofecoxib or no drug for 21 days. Tumor growth was assessed by comparing volume before and after treatment. In vitro, rofecoxib decreased gene expression of cyclin D1/PRAD1, a key component of cell cycle progression, while increasing expression of several cell cycle arrest genes, including p21/WAF1, p33/ING, GADD34, and GADD45 (P <0.05). In vivo, tumor growth was significantly reduced in treated vs. control mice (P <0.05). No systemic toxicity was observed in mice receiving rofecoxib. These data suggest that rofecoxib slows the growth of human pancreatic cancer through changes in gene expression that favor cell cycle arrest.

KW - Cell cycle

KW - Cyclooxygenase-2

KW - Microarray

KW - Pancreas cancer

KW - Rofecoxib

UR - http://www.scopus.com/inward/record.url?scp=15944388899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944388899&partnerID=8YFLogxK

U2 - 10.1016/S1091-255X(02)00061-6

DO - 10.1016/S1091-255X(02)00061-6

M3 - Article

C2 - 12504222

AN - SCOPUS:15944388899

VL - 6

SP - 838

EP - 844

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 6

ER -